161 related articles for article (PubMed ID: 29923251)
1. Use of proton pump inhibitors and risk of pancreatic cancer.
Hicks B; Friis S; Pottegård A
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):926-930. PubMed ID: 29923251
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population-based case-control study.
Hálfdánarson ÓÖ; Fall K; Ogmundsdottir MH; Lund SH; Steingrímsson E; Ogmundsdottir HM; Zoega H
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):471-478. PubMed ID: 30565786
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study.
Bradley MC; Murray LJ; Cantwell MM; Hughes CM
Br J Cancer; 2012 Jan; 106(1):233-9. PubMed ID: 22108522
[TBL] [Abstract][Full Text] [Related]
4. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
5. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.
Brusselaers N; Sadr-Azodi O; Engstrand L
J Gastroenterol; 2020 Apr; 55(4):453-461. PubMed ID: 31811561
[TBL] [Abstract][Full Text] [Related]
6. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
7. Use of Proton Pump Inhibitors and the Risk of Listeriosis: A Nationwide Registry-based Case-Control Study.
Kvistholm Jensen A; Simonsen J; Ethelberg S
Clin Infect Dis; 2017 Apr; 64(7):845-851. PubMed ID: 28013257
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
9. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
[TBL] [Abstract][Full Text] [Related]
10. Use of Proton Pump Inhibitors and Risk of Pancreatic Cancer: A Nationwide Case-Control Study Based on the French National Health Data System (SNDS).
Lassalle M; Le Tri T; Afchain P; Camus M; Kirchgesner J; Zureik M; Dray-Spira R
Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):662-669. PubMed ID: 34937794
[TBL] [Abstract][Full Text] [Related]
11. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies.
Liu P; McMenamin ÚC; Johnston BT; Murchie P; Iversen L; Lee AJ; Vissers PAJ; Cardwell CR
Br J Cancer; 2020 Jul; 123(2):307-315. PubMed ID: 32367073
[TBL] [Abstract][Full Text] [Related]
12. Prenatal exposure to acid-suppressive drugs and the risk of childhood asthma: a population-based Danish cohort study.
Andersen AB; Erichsen R; Farkas DK; Mehnert F; Ehrenstein V; Sørensen HT
Aliment Pharmacol Ther; 2012 May; 35(10):1190-8. PubMed ID: 22443179
[TBL] [Abstract][Full Text] [Related]
13. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study.
Robertson DJ; Larsson H; Friis S; Pedersen L; Baron JA; Sørensen HT
Gastroenterology; 2007 Sep; 133(3):755-60. PubMed ID: 17678921
[TBL] [Abstract][Full Text] [Related]
15. Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population.
Lee JK; Merchant SA; Schneider JL; Jensen CD; Fireman BH; Quesenberry CP; Corley DA
Am J Gastroenterol; 2020 May; 115(5):706-715. PubMed ID: 32205645
[TBL] [Abstract][Full Text] [Related]
16. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.
Pouwels S; Lalmohamed A; Souverein P; Cooper C; Veldt BJ; Leufkens HG; de Boer A; van Staa T; de Vries F
Osteoporos Int; 2011 Mar; 22(3):903-10. PubMed ID: 20585937
[TBL] [Abstract][Full Text] [Related]
17. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
18. Colorectal cancer risk in relation to use of acid suppressive medications.
Chubak J; Boudreau DM; Rulyak SJ; Mandelson MT
Pharmacoepidemiol Drug Saf; 2009 Jul; 18(7):540-4. PubMed ID: 19367565
[TBL] [Abstract][Full Text] [Related]
19. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.
Lam JR; Schneider JL; Quesenberry CP; Corley DA
Gastroenterology; 2017 Mar; 152(4):821-829.e1. PubMed ID: 27890768
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies.
Tran KT; McMenamin ÚC; Hicks B; Murchie P; Thrift AP; Coleman HG; Iversen L; Johnston BT; Lee AJ; Cardwell CR
Aliment Pharmacol Ther; 2018 Jul; 48(1):55-64. PubMed ID: 29741272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
